Sifting through countless of stocks in the Life Sciences Tools & Services industry can be tedious, and sometimes two stocks are just too similar to judge which is the better investment. If you’re on the fence about investing in 10x Genomics, Inc. or Thermo Fisher Scientific Inc. because you’re not sure how they measure up, it’s important to compare them on a few factors before making your decision.

Read on to learn how 10x Genomics, Inc. and Thermo Fisher Scientific Inc. compare based on key financial metrics to determine which better meets your investment needs.

About 10x Genomics, Inc. and Thermo Fisher Scientific Inc.

10x Genomics, Inc. develops and sells instruments, consumables, and software for analyzing biological systems in the United States, rest of the Americas, Europe, the Middle East, Africa, China, and the rest of the Asia Pacific. The company offers Chromium platform, a single cell portfolio that enables analysis of individual biological components, as well as includes microfluidic chips and related consumables, Chromium X Series, and Chromium instruments; and QuantumScale single cell RNA and single cell methylation kits. It also provides Visium platform, a spatial analysis platform that uses high density DNA arrays to encode the physical location of biological analytes within a sample. This platform includes HD WT panel gene expression, and HD 3’ gene expression assays, as well as the Visium CytAssist, an instrument designed to simplify and optimize the Visium solution workflow by facilitating the transfer of transcriptomic analytes from standard glass slides to Visium slides. In addition, the company offers Xenium Analyzer instrument enables researchers to detect and preserve the cellular location of hundreds of RNA targets directly in a fresh frozen or FFPE tissue section without the need for conventional sequencing; and slides and reagents. Further, it provides various software products comprising Cell Ranger, a scRNA-seq processing pipeline in scientific literature; Loupe Browser, which enables intuitive single-cell, spatial, and multiomic data visualization; and Xenium Explorer that enables intuitive in situ data visualization, which allows researchers to explore subcellular gene expression, spatial organization, and tissue-scale patterns. The company serves various academic, government, biopharmaceutical, biotechnology, and other institutions. The company was formerly known as 10X Technologies, Inc. and changed its name to 10x Genomics, Inc. in November 2014. 10x Genomics, Inc. was incorporated in 2012 and is headquartered in Pleasanton, California.

Thermo Fisher Scientific Inc. provides life sciences solutions, analytical instruments, specialty diagnostics, and laboratory products and biopharma services internationally. It operates through four segments: Life Sciences Solutions, Analytical Instruments, Specialty Diagnostics, and Laboratory Products and Biopharma Services. The Life Sciences Solutions segment includes reagents, instruments, and consumables for biological and medical research; discovery and production of drugs and vaccines; and diagnosis of infections and diseases. Its Analytical Instruments segment provides instruments, consumables, software, and services for pharmaceutical, biotechnology, academic, government, environmental, and other research and industrial markets, as well as clinical laboratories. The Specialty Diagnostics segment offers clinical diagnostics products, such as liquid ready-to-use and lyophilized immunodiagnostic reagent kits, calibrators, controls, protein detection assays, and instruments; immunodiagnostic offerings comprising developing, manufacturing, and marketing of complete blood-test systems for the clinical diagnosis and monitoring of allergy, asthma and autoimmune diseases; microbiology offerings, such as dehydrated and prepared culture media, collection and transport systems, instrumentation and consumables to detect pathogens in blood, diagnostic and rapid direct specimen tests, quality-control products, and associated products; transplant diagnostics products, including human leukocyte antigen typing and testing for the organ transplant market; and healthcare market channel offerings. Its Laboratory Products and Biopharma Services segment provides laboratory products, research and safety market channel, and pharma services and clinical research. Thermo Fisher Scientific Inc. was founded in 1956 and is headquartered in Waltham, Massachusetts.

Latest Life Sciences Tools & Services and 10x Genomics, Inc., Thermo Fisher Scientific Inc. Stock News

As of September 23, 2026, 10x Genomics, Inc. had a $9.8 billion market capitalization, compared to the Life Sciences Tools & Services median of $3.6 million. 10x Genomics, Inc.’s stock is up 415.7% in 2026, up 9.3% in the previous five trading days and up 479.45% in the past year.

Currently, 10x Genomics, Inc. does not have a price-earnings ratio. 10x Genomics, Inc.’s trailing 12-month revenue is $616.9 million with a -12.2% net profit margin. Year-over-year quarterly sales growth most recently was -12.7%. Analysts expect adjusted earnings to reach $0.105 per share for the current fiscal year. 10x Genomics, Inc. does not currently pay a dividend.

As of September 23, 2026, Thermo Fisher Scientific Inc. had a $246.0 billion market cap, putting it in the 99th percentile of all stocks. Thermo Fisher Scientific Inc.’s stock is up 17.1% in 2026, up 3% in the previous five trading days and up 40.07% in the past year.

Currently, Thermo Fisher Scientific Inc.’s price-earnings ratio is 35.8. Thermo Fisher Scientific Inc.’s trailing 12-month revenue is $46.3 billion with a 15.0% net profit margin. Year-over-year quarterly sales growth most recently was 10.5%. Analysts expect adjusted earnings to reach $25.131 per share for the current fiscal year. Thermo Fisher Scientific Inc. currently has a 0.3% dividend yield.

How We Compare 10x Genomics, Inc. and Thermo Fisher Scientific Inc. Stock Grades

Stock evaluation requires access to huge amounts of data and the knowledge and time to sift through it all, make sense of financial ratios, read income statements and analyze recent stock movements. AAII created A+ Investor, a robust data suite that condenses data research in an actionable and customizable way suitable for investors of all knowledge levels, to help investors streamline and work through such data.

AAII’s proprietary stock grades come with A+ Investor. These offer intuitive A‐F grades for each of five key investing factors: value, growth, momentum, earnings estimate revisions and quality. Here, we’ll take a closer look at 10x Genomics, Inc. and Thermo Fisher Scientific Inc.’s stock grades to see how they measure up against one another.

Learn more about A+ Investor here!

Sign Up to Receive a Free Special Report Showing How A+ Grades Can Help You Make Smarter Investment Decisions

10x Genomics, Inc. and Thermo Fisher Scientific Inc.’s Quality Grades

Company	Ticker	Quality
10x Genomics, Inc.	TXG	B
Thermo Fisher Scientific Inc.	TMO	B

Like the Value Grade, AAII’s A+ Investor Quality Grade comes from the percentile rank of key metrics. Specifically, the Quality Score is the percentile rank of the average of the percentile ranks of return on assets (ROA), return on invested capital (ROIC), gross profit relative to assets, buyback yield, change in total liabilities to assets, accruals, Z double prime bankruptcy risk (Z) score and the F-Score.

The score is variable, meaning it can consider all eight measures or, should any of the eight measures not be valid, the remaining measures that are valid. To be assigned a Quality Score, stocks must have a valid (non-null) measure and corresponding ranking for at least four of the eight quality measures.

The Quality Score is used to assess the underlying “quality” of a particular stock. A higher-quality stock possesses traits associated with upside potential and reduced downside risk. Backtesting of the Quality Grade shows that stocks with higher grades, on average, outperformed stocks with lower grades over the period of 1998 through 2019.

Stocks receive better grades (higher scores) for having higher scores for the quality subcomponents and worse grades (lower scores) for lower scores for the subcomponents.

10x Genomics, Inc. has a Quality Score of 68, which is Strong. Thermo Fisher Scientific Inc. has a Quality Score of 65, which is Strong.

The Quality Grade Winner: It’s a Tie!

Looking at the Quality Grade breakdown above, both 10x Genomics, Inc. and Thermo Fisher Scientific Inc. have a grade of B. For investors who focus solely on a company’s overall quality, you will need to conduct further research into both companies to see if they are a good fit for your portfolio. As a good rule of thumb, you should always analyze multiple factors based on a wide range of metrics before choosing a company to invest in.

10x Genomics, Inc. and Thermo Fisher Scientific Inc.’s Momentum Grades

Company	Ticker	Momentum
10x Genomics, Inc.	TXG	A
Thermo Fisher Scientific Inc.	TMO	A

Momentum grades help to uncover stocks experiencing anomalously high rates of return; research finds that stocks with high relative levels of momentum tend to outperform, whereas those with low levels of momentum tend to continue underperforming. Momentum is based on the price change of a stock over a specified period relative to all other stocks.

Typically, AAII looks at the weighted relative strength over the trailing four quarters. The weighted four-quarter relative strength rank is the relative price change for each of the past four quarters. The most recent quarterly price change is given a weight of 40% and each of the three previous quarters are given a weighting of 20%.

10x Genomics, Inc. has a Momentum Score of 99, which is Very Strong. Thermo Fisher Scientific Inc. has a Momentum Score of 84, which is Very Strong.

The Momentum Grade Winner: It’s a Tie!

Looking at the Momentum Grade breakdown above, both 10x Genomics, Inc. and Thermo Fisher Scientific Inc. have a grade of A. For those who focus solely on a company’s momentum, further research will need to be conducted into both companies to see if they fit your individual needs as an investor.

10x Genomics, Inc. and Thermo Fisher Scientific Inc.’s Estimate Revisions Grades

Company	Ticker	Earnings Estimate
10x Genomics, Inc.	TXG	C
Thermo Fisher Scientific Inc.	TMO	B

Earnings estimate revisions scores consider the magnitude of a company’s earnings surprise in its last two reported fiscal quarters. Often, positive surprises beget further positive surprises‐or at least continued sales growth (the exact opposite is generally true, too).

Estimate revisions offer an indication of what analysts are thinking about the short-term prospects of a firm. Estimate revisions are based on the statistical significance of a firm’s last two quarterly earnings surprises and the percentage change in its consensus estimate for the current fiscal year over the past month and past three months.

10x Genomics, Inc. has a Earnings Estimate Score of 59, which is Neutral. Thermo Fisher Scientific Inc. has a Earnings Estimate Score of 73, which is Positive.

The Earnings Estimate Revisions Grade Winner: Thermo Fisher Scientific Inc.

As you can clearly see from the Earnings Estimate Revisions Grade breakdown above, Thermo Fisher Scientific Inc. has a better Earnings Estimate Revisions Grade than 10x Genomics, Inc.. For those who are specifically looking for companies with better short-term prospects when compared to other companies in the same industry, Thermo Fisher Scientific Inc. could be a good stock to invest in. However, it’s important to analyze multiple factors based on a wide range of metrics before deciding whether to buy.

Other 10x Genomics, Inc. and Thermo Fisher Scientific Inc. Grades

In addition to Estimate Revisions, Quality and Momentum, A+ Investor also provides grades for Value and Growth.

Growth investing builds on the idea that stocks of companies exhibiting strong, consistent and prolonged growth outperform those of slower-growth companies. AAII measures growth through consistency of annual sales growth, five-year sales growth rankings adjusted for extreme levels, and consistency of positive annual cash from operations.

Successful stock investing involves buying low and selling high, so stock valuation is an important consideration for stock selection. Buying stocks that are going to go up typically means buying stocks that are undervalued in the first place, although momentum investors may argue that point.

These 2 key factors, when combined with the above, provide a holistic view into a particular stock. Further, by joining A+ Investor you can see whether 10x Genomics, Inc. and Thermo Fisher Scientific Inc. pass any of our 60+ stock screens that have outperformed the market since their creation.

So, Which Is the Better Investment, 10x Genomics, Inc. or Thermo Fisher Scientific Inc. Stock?

Overall, 10x Genomics, Inc. stock has a Momentum Score of 99, Estimate Revisions Score of 59 and Quality Score of 68.

Thermo Fisher Scientific Inc. stock has a Momentum Score of 84, Estimate Revisions Score of 73 and Quality Score of 65.

Comparing 10x Genomics, Inc. and Thermo Fisher Scientific Inc.’s grades, scores and metrics can act as a solid basis to determine whether they may be a good investment or not. You’ll also want to look at your portfolio’s asset allocation as well as your risk tolerance and financial goals to see if either of these stocks would make a good fit for you. AAII can help you figure out which investments align with your individual needs and preferences.

Investors are encouraged to do their own due diligence and research. In this way, individuals can effectively become managers of their own assets‐without having to rely on others for financial independence. You can count on AAII for timeless articles on financial planning and stock-picking, unbiased research and actionable analysis.

A+ Investor adds to our qualitative teaching with a powerful data suite to help you whittle down investment choices to find stocks, exchange-traded funds (ETFs) or mutual funds that meet your needs.

AAII Disclaimer

We make no representations or warranties that any investor will, or is likely to, achieve profits similar to those shown, because past, hypothetical or simulated performance is not necessarily indicative of future results. Before making an investment decision, you should consider your circumstances and whether the information on our content is applicable to your situation. This information was prepared in good faith, and we accept no liability for any errors or omissions. The full disclaimer can be read here.